FIGURE 1.

Model schema. Health states incorporated into the model are shown in circles, and possible transitions between health states are depicted by arrows. All patients enter the model in the Chemotherapy state (docetaxel–cyclophosphamide or doxorubicin–cyclophosphamide) and move to Disease-Free state after completion of chemotherapy treatment. Chemotherapy-related adverse events could occur during Chemotherapy state [that is, chemotherapy-induced nausea and vomiting (cinv) or febrile neutropenia (fn)] or after transition to Disease-Free state [that is, acute myeloid leukemia (aml) or myelodysplasia (mds), or congestive heart failure (chf)]. Patients in Disease-Free state could develop Local Relapse or Distant Relapse. Death might occur with or without relapse or as a result of chemotherapy adverse events.